Login to Your Account



Study Confirms Zytiga's Benefit in Earlier-Stage Prostate Cancer

By Nuala Moran
Staff Writer

Wednesday, December 12, 2012
LONDON – Scientists at the Institute of Cancer Research (ICR) in London published Tuesday details of the Phase III trial of Johnson & Johnson's prostate cancer drug Zytiga (abiraterone acetate) in men who had not received chemotherapy, a day after the FDA agreed to a label extension allowing the drug to be used at that earlier stage of the disease.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription